Drug class in one race
TROP2 drugs for HR+/HER2- Metastatic Breast Cancer
3 tracked TROP2 drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the TROP2 page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
2 approved / phase 41 Phase 3
Head-to-head evidence: Datopotamab Deruxtecan vs Sacituzumab Govitecan · Sacituzumab Govitecan vs Sacituzumab Tirumotecan